Cosmetic compoition comprising glutathione precusors and lignan compounds derived from magnolia

Abstract

The present invention relates to a cosmetic composition comprising a glutathione precursor and a lignan-based compound derived from magnolia, and provides a cosmetic composition having an excellent antioxidant effect by securing the efficiency of a complex synergistic combination of honokiol and an antioxidant amino acid.

Description

Technology Field

[0001] The present invention relates to a cosmetic composition comprising a glutathione precursor and a lignan-based compound derived from magnolia. Background Technology

[0002] Skin aging is a complex physiological phenomenon caused by intrinsic factors (such as increasing age and decreased metabolism) and extrinsic factors (such as ultraviolet rays, environmental pollution, and inflammatory responses). Its primary cause lies in cell damage and the weakening of the antioxidant defense network caused by reactive oxygen species (ROS). ROS damage collagen, elastin, and cell membrane lipids in the dermal layer of the skin, leading to wrinkle formation and a decline in elasticity; consequently, the development of antioxidant materials to inhibit these effects has been continuously pursued in the fields of cosmetics and pharmaceuticals. Furthermore, it has been reported that ROS not only damages collagen, elastin, and cell membrane lipids in the dermal layer to cause wrinkle formation and reduced elasticity, but also directly affects the melanin production pathway. Since ROS increases melanin production by promoting tyrosinase activity or increasing the expression of MITF (Microphthalmia-associated transcription factor), they act as major intrinsic triggers for skin hyperpigmentation and the formation of melasma. Accordingly, antioxidant materials that inhibit oxidative stress or scavenge ROS are being actively utilized in cosmetic compositions aimed not only at alleviating skin aging but also at providing whitening effects.

[0003] In the skin, glutathione (GSH) serves as a representative endogenous antioxidant and reduction regulator, playing a role in directly removing ROS and reducing oxidized proteins. GSH is synthesized from glutamine, cysteine, and glycine through a two-step enzymatic reaction (γ-glutamylcysteine ​​synthetase and glutathione synthetase) and is known as a key biosynthetic pathway for maintaining an intracellular reducing environment. In particular, combinations containing glycine, glutamine, and cysteine ​​(or N-acetyl-cysteine) simultaneously have been reported to significantly increase the GSH content in skin cells compared to each component alone or a two-component combination.

[0004] For example, U.S. Patent Publication US 6,149,925 suggests that the amount of GSH biosynthesis in HaCaT cells increases synergistically compared to a single component in a topical composition containing these three components at a level of 0.5-3 wt%. These results suggest that the GAP combination can be utilized not merely as a simple source of amino acids, but as an antioxidant enhancement system with effects of GSH regeneration and oxidative stress reduction.

[0005] US Patent 11,077,039 B2 describes that when the GAP (Glycine-Glutamine-Cystine) combination is used in combination with a nicotinamide compound, the skin antioxidant and whitening effects are enhanced. However, due to the water solubility limit and low transdermal absorption rate of these precursor amino acids, a relatively high concentration (at the level of a few percent) is required.

[0006] As such, glutathione and its precursor (GAP) have been studied extensively for the purpose of alleviating skin oxidative stress, but limitations in efficacy at low concentrations and the lack of a stable skin delivery system remain challenges to be addressed.

[0007] Meanwhile, Honokiol and its homolog Magnolol are magnolias (Magnolia officinalis Lignan compounds derived from tree bark are known as natural materials with powerful antioxidant, anti-inflammatory, antibacterial, and whitening activities. They have a mechanism of action that alleviates cell damage and inflammation through inhibition of ROS production, inhibition of NO synthesis, and regulation of NF-κB and MAPK pathways.

[0008] In particular, European registered patent EP 2,070,523 B1 suggests that a mixture of magnolol and honokiol exhibits a synergistic effect in inhibiting the production of NO, an inflammatory mediator, and can be applied as a topical composition for cosmetics and the treatment of skin diseases.

[0009] US registered patent US 12,016,895 B2 discloses a skin improvement composition containing honokiol and magnolol, which are derived from the bark of the Magnolia officinalis tree, as active ingredients, and reports that honokiol has the effect of relieving oxidative stress by removing reactive oxygen species (ROS) in the skin, and brightening skin tone and alleviating pigmentation by inhibiting tyrosinase activity and reducing melanin biosynthesis.

[0010] Korean published patent KR 10-2006-0014203 A also describes a technology for applying honokiol / magnolol for antibacterial and anti-inflammatory purposes related to acne.

[0011] As such, while various combination studies are being conducted on magnolol and honokiol as natural antioxidants, there is still a lack of technical disclosure regarding synergistic effects when used in combination with amino acid-based antioxidants (GAP). Furthermore, although the aforementioned technologies aim to defend against ROS and inhibit aging by strengthening the skin's antioxidant network, they still have limitations in terms of securing the efficiency of complex synergistic combinations. Prior art literature

[0012] 1. US Published Patent US 6,149,9252. US Registered Patent US 11,077,039 B23. European Registered Patent EP 2,070,523 B14. US Registered Patent US 12,016,895 B25. Korean Published Patent KR 10-2006-0014203 A The problem to be solved

[0013] The present invention, aimed at solving the aforementioned problems, provides a cosmetic composition that secures the efficiency of a complex synergistic combination of magnolia-derived lignan compounds and antioxidant amino acids.

[0014] The present invention aims to provide a functional cosmetic composition comprising a glutathione precursor and honokiol that simultaneously achieves a GSH synthesis-promoting effect and a direct ROS scavenging effect to inhibit skin oxidative stress, inflammation, melanin production, and photoaging.

[0015] The present invention aims to provide a composition capable of providing stable and long-term antioxidant and whitening effects without skin irritation through the optimal concentration and weight ratio of a complex combination.

[0016] The problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem

[0017] The present invention, for solving the aforementioned problem, provides a cosmetic composition comprising a glutathione precursor and a lignan-based compound derived from magnolia.

[0018] According to one embodiment of the present invention, the glutathione precursor may include cysteine ​​or cystine, a glutamic acid source, and glycine.

[0019] According to one embodiment of the present invention, the glutamic acid source may be one or more selected from glutamine, glutamic acid, pyroglutamic acid and salts thereof.

[0020] According to one embodiment of the present invention, the magnolia-derived lignan compound may be one or more selected from honokiol and magnolol.

[0021] According to one embodiment of the present invention, the glutathione precursor is included in an amount of 0.000001 to 10 weight% relative to the total weight of the cosmetic composition, and the magnolia-derived lignan compound may be included in an amount of 0.000001 to 10 weight% relative to the total weight of the cosmetic composition.

[0022] According to one embodiment of the present invention, the glutathione precursor and the magnolia-derived lignan compound may be included in a weight ratio of 1:0.1 to 30.

[0023] According to one embodiment of the present invention, the cosmetic composition may be for one or more uses selected from the group consisting of improving skin wrinkles, improving skin elasticity, improving skin moisture, improving skin barrier, skin whitening, inhibiting inflammation, and antioxidant.

[0024] According to one embodiment of the present invention, the cosmetic composition may be one or more formulations selected from the group consisting of softening lotion, nourishing lotion, astringent lotion, skin toner, lotion, essence, cream, massage cream, pack, makeup base, BB cream, foundation, powder, cleansing foam, cleansing cream, and cleansing water. Effects of the invention

[0026] The present invention provides a cosmetic composition that ensures the efficiency of a complex synergistic combination of a magnolia-derived lignan compound and an antioxidant amino acid, and exhibits an excellent antioxidant effect.

[0027] The composition of the present invention exhibits excellent skin wrinkle improvement, skin elasticity improvement, skin hydration improvement, skin barrier improvement, skin whitening, inflammation improvement and inhibition, and antioxidant effects.

[0028] The effects of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by a person skilled in the art from the description below. Specific details for implementing the invention

[0030] The advantages and features of the present invention and the methods for achieving them will become clear by referring to the embodiments described below in detail together with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below but may be implemented in various different forms. These embodiments are provided merely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the present invention, and the present invention is defined only by the scope of the claims.

[0031] The terms used herein are for describing the embodiments and are not intended to limit the invention. In this specification, the singular form includes the plural form unless specifically stated otherwise in the text. As used herein, "comprises" and / or "comprising" do not exclude the presence or addition of one or more other components in addition to the components mentioned. Throughout the specification, the same reference numerals refer to the same components, and "and / or" includes each of the components mentioned and all combinations of one or more.

[0032] Unless otherwise defined, all terms used herein (including technical and scientific terms) may be used in a meaning commonly understood by those skilled in the art to which the present invention pertains. Additionally, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise.

[0033] The present invention provides a cosmetic composition comprising a glutathione precursor and a lignan compound derived from Magnolia. The composition ensures the efficiency of a complex synergistic combination of a lignan compound derived from Magnolia and an antioxidant amino acid, thereby exhibiting an excellent antioxidant effect. The composition strengthens the intracellular reducing environment through the complementary action of the glutathione precursor and the lignan compound derived from Magnolia, and significantly improves the ability to defend against oxidative stress by efficiently removing reactive oxygen species (ROS). In particular, since the lignan compound derived from Magnolia possesses lipophilicity, it promotes the permeability of water-soluble amino acid precursors through the cell membrane and activates the GSH biosynthetic pathway, thereby enabling the expression of antioxidant activity exceeding that of Vitamin C even at low concentrations.

[0034] According to one embodiment of the present invention, the glutathione precursor may include cysteine ​​or cystine, a glutamic acid source, and glycine. Since these components complete the precursor step of GSH biosynthesis, they directly increase the concentration of glutathione in the skin, thereby simultaneously improving ROS scavenging ability and cell regeneration ability. This allows for complex skin improvement effects, such as skin tone improvement, elasticity restoration, and wrinkle reduction.

[0035] According to one embodiment of the present invention, the cysteine, cystine, or glycine of the present invention also comprises salts thereof, esters, and salts of esters. The salts, esters, and salts of esters are not specifically limited as long as they are suitable for topical application. The ester of cystine (or glycine) is generally a C1-C8 ester or its salt, or largely a C1-C5 ester or its salt, or generally a C1-C3 ester or its salt. It may be a methyl and ethyl ester of cystine (or cysteine, or glycine) or its salt. However, cystine may be pure cystine itself, not in the form of its salt, ester, or salt of ester. Cysteine ​​may be pure cysteine ​​itself, not in the form of its salt, ester, or salt of ester. Glycine may be pure glycine itself, not in the form of its salt, ester, or salt of ester.

[0036] According to one embodiment of the present invention, the glutamic acid source may be one or more selected from glutamine, glutamic acid, pyroglutamic acid, and salts thereof. By efficiently providing glutamic acid required for the glutathione (GSH) biosynthesis pathway within cells, these components can stabilize the reducing environment of skin cells and enhance antioxidant defense capabilities. Specifically, it may be glutamine. Glutamine contributes to ensuring the sustainability of GSH synthesis as a major precursor converted into glutamic acid through cellular metabolism, and glutamic acid can induce a rapid antioxidant response by directly participating in the GSH biosynthesis pathway.

[0037] According to one embodiment of the present invention, the glutamic acid source may include salt forms of glutamine, glutamic acid, and pyroglutamic acid, and such salts have the advantage of improving water solubility and formulation stability, thereby improving uniform dispersion and storage stability within a cosmetic composition. In particular, when present in the form of a sodium salt, potassium salt, ammonium salt, or organic salt, it rapidly dissociates upon application to the skin, thereby efficiently providing active ingredients and facilitating the supply of glutamic acid required for intracellular glutathione (GSH) biosynthesis.

[0038] According to one embodiment of the present invention, the lignan-based compound derived from magnolia may be one or more selected from honokiol and magnolol. Specifically, it may be honokiol. Due to the polyphenol structure of these lignan-based compounds, reactive oxygen species (ROS) are effectively scavenged, thereby reducing cellular oxidative stress. By acting uniformly across the stratum corneum and dermis, it can inhibit oxidative damage to collagen and elastin and enhance skin elasticity and wrinkle improvement effects.

[0039] According to one embodiment of the present invention, the glutathione precursor may be included in an amount of 0.000001 to 10 weight% relative to the total weight of the cosmetic composition. Specifically, it may be included in an amount of 0.000001 to 5 weight% relative to the total weight of the cosmetic composition, more specifically 0.000001 to 1 weight%. When included within the above range, skin irritation is minimized while activating the intracellular antioxidant network, and a compositional state that is skin-friendly and has excellent transdermal absorption is maintained, thereby enabling stable expression of efficacy.

[0040] According to one embodiment of the present invention, the glutathione precursor may comprise cysteine ​​or cystine, a glutamic acid source, and glycine, and may comprise 0.0000005 to 5 weight% of cysteine ​​or cystine, 0.0000005 to 10 weight% of a glutamic acid source, and 0.0000001 to 10 weight% of glycine relative to the total weight of the cosmetic composition. Specifically, it may comprise 0.0000005 to 3 weight% of cysteine ​​or cystine, 0.0000005 to 5 weight% of a glutamic acid source, and 0.0000001 to 5 weight% of glycine relative to the total weight of the cosmetic composition. More specifically, the cosmetic composition may contain 0.0000005 to 0.5 weight% of cysteine ​​or cystine, 0.0000005 to 1 weight% of a glutamic acid source, and 0.0000001 to 1 weight% of glycine, based on the total weight of the cosmetic composition. When included within the above ranges, precursors necessary for glutathione (GSH) biosynthesis are supplied to skin cells in stages, thereby stably maintaining an intracellular reducing environment. In particular, cysteine ​​or cystine acts as a key component for GSH synthesis, while the glutamic acid source and glycine regulate amino acid metabolic balance, simultaneously improving the sustainability and efficiency of the antioxidant reaction. Specifically, the glutamic acid source may be glutamine.

[0041] According to one embodiment of the present invention, the magnolia-derived lignan compound may be included in an amount of 0.000001 to 10 weight% relative to the total weight of the cosmetic composition. Specifically, it may be included in an amount of 0.000001 to 5 weight% relative to the total weight of the cosmetic composition, more specifically 0.000001 to 1 weight%. When included within the above range, the strong ROS scavenging ability due to the polyphenol structure of the magnolia-derived lignan compound is exerted, thereby preventing oxidative damage to cell membrane lipids and proteins, and simultaneously exhibiting anti-inflammatory and melanin biosynthesis inhibitory effects, thereby providing skin tone uniformization and photoaging inhibition effects.

[0042] According to one embodiment of the present invention, the magnolia-derived lignan compound may be one or more selected from honokiol and magnolol, and one or more selected from honokiol and magnolol may be included in an amount of 0.000001 to 10 weight% relative to the total weight of the cosmetic composition. Specifically, it may be included in an amount of 0.000001 to 5 weight%, more specifically 0.000001 to 1 weight% relative to the total weight of the cosmetic composition. When included within the above range, honokiol and / or magnolol are uniformly distributed in the stratum corneum and dermis of the skin, thereby inhibiting oxidative damage to collagen and elastin and effectively expressing skin elasticity and wrinkle improvement effects.

[0043] According to one embodiment of the present invention, the glutathione precursor and the magnolia-derived lignan compound may be included in a weight ratio of 1:0.1 to 30. Specifically, they may be included in a weight ratio of 1:0.5 to 20, and more specifically, in a weight ratio of 1:1 to 15. When included within the above range, the complementary antioxidant activity between the two components is maximized, resulting in significantly enhanced antioxidant and whitening synergistic effects compared to a single component. When included within the above range, the lipid-soluble characteristics of honokiol and the water-soluble characteristics of the amino acid precursor are balanced, thereby exhibiting the advantage of uniformly expressing an oxidation-inhibiting effect throughout the skin layer.

[0044] According to one embodiment of the present invention, the glutathione precursor may include cysteine ​​or cystine, a glutamic acid source, and glycine, and the cysteine ​​or cystine : glutamic acid source : glycine may be included in a weight ratio of 1 : 0.1 to 30 : 0.1 to 30. Specifically, the cysteine ​​or cystine : glutamic acid source : glycine may be included in a weight ratio of 1 : 0.1 to 10 : 0.1 to 10, more specifically in a weight ratio of 1 : 0.1 to 15 : 0.1 to 15, more specifically in a weight ratio of 1 : 0.1 to 7 : 0.1 to 7, more specifically in a weight ratio of 1 : 0.1 to 5 : 0.1 to 5, and more specifically in a weight ratio of 1 : 1 to 5 : 1 to 5.

[0045] According to one embodiment of the present invention, the total weight of the cysteine ​​and cystine and the glutamic acid source may be included in a weight ratio of 1:0.1 to 30. Specifically, the cysteine ​​and cystine: glutamic acid source may be included in a weight ratio of 1:0.1 to 10, more specifically in a weight ratio of 1:0.1 to 15, more specifically in a weight ratio of 1:0.1 to 7, more specifically in a weight ratio of 1:0.1 to 5, and more specifically in a weight ratio of 1:1 to 5.

[0046] According to one embodiment of the present invention, the weight of the glutamic acid source and the weight of glycine may be specifically in a weight ratio of 1:0.05 to 20, more specifically in a weight ratio of 1:0.125 to 8, and more specifically in a weight ratio of 1:0.33 to 1.

[0047] Specifically, the glutamic acid source may be glutamine. When included within the above range, the functions performed by each precursor in the glutathione biosynthetic pathway act complementarily, maximizing the efficiency of GSH production. Within this weight ratio range, balanced metabolism is maintained without excessive consumption of specific precursors, allowing the intracellular antioxidant defense system to be stably activated.

[0048] According to one embodiment of the present invention, the glutathione precursor comprises cysteine ​​or cystine, a glutamic acid source, and glycine, and the magnolia-derived lignan compound may be one or more selected from honokiol and magnolol, wherein one or more of cysteine ​​or cystine : glutamic acid source : glycine : honokiol and magnolol may be included in a weight ratio of 1 : 0.1 to 10 : 0.1 to 10 : 0.1 to 30. Specifically, one or more of cysteine ​​or cystine : glutamic acid source : glycine : honokiol and magnolol may be included in a weight ratio of 1 : 0.1 to 7 : 0.1 to 7 : 0.5 to 20. More specifically, they may be included in a weight ratio of 1 : 0.1 to 5 : 0.1 to 5 : 1 to 15.

[0049] According to one embodiment of the present invention, specifically, the glutamic acid source may be included in a weight ratio of 1:0.001 to 300, more specifically 1:0.01 to 200, more specifically 1:0.1 to 100, more specifically 1:1 to 40, and more specifically 1:1 to 15 with respect to the total weight of honokiol and magnolol.

[0050] When included within the above range, an intracellular antioxidant base is stably formed by water-soluble amino acid precursors, and the inhibitory effect on oxidative stress can be complementarily amplified by lipophilic honokiol and / or magnolol acting throughout the cell membrane and skin tissue. Specifically, the glutamic acid source may be glutamine.

[0051] According to one embodiment of the present invention, the cosmetic composition may be for one or more uses selected from the group consisting of improving skin wrinkles, improving skin elasticity, improving skin moisture, improving skin barrier, skin whitening, inhibiting inflammation, and antioxidant.

[0052] According to one embodiment of the present invention, the cosmetic composition of the present invention may further include cosmetically acceptable carriers or additives. Examples include, but are not limited to, fatty substances, organic solvents, solvents, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, emulsifiers, fillers, metal ion chelating agents, chelating agents, preservatives, vitamins, blockers, humectants, oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, etc., and may include all known substances applicable to cosmetic compositions.

[0053] According to one embodiment of the present invention, the cosmetic composition may be formed in one or more formulations selected from the group consisting of softening lotion, nourishing lotion, astringent lotion, skin toner, lotion, essence, cream, massage cream, pack, makeup base, BB cream, foundation, powder, cleansing foam, cleansing cream, and cleansing water, but is not limited thereto, and may be formed in any known formulation.

[0055] Hereinafter, embodiments of the present invention will be described in detail with reference to the attached drawings.

[0056] Prior to the explanation, the meanings of the terms used in this specification are briefly explained. However, since the explanation of terms is intended to aid in understanding this specification, it should be noted that they are not used to limit the technical scope of the invention unless explicitly stated to be a limiting factor.

[0058] DPPH radical scavenging activity analysis method

[0059] To measure the antioxidant effect, the antioxidant effect (free radical scavenging rate) was measured using the DPPH method. The DPPH method measures the antioxidant effect based on reducing power using a free radical called the DPPH (2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl) free radical. The free radical scavenging rate (%) at a wavelength of 517 nm is measured by comparing the degree to which the absorbance decreases due to the reduction of DPPH by the test substance with the absorbance of the blank solution. As the reagent used, 61.88 mg of a 0.1 mM solution of 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl free radical (Aldrich Chem. Co., MW=618.76) was dissolved in methanol to make 100 ml.

[0060] As a measurement method, ① 0.02 ml of the sample solution is added to 1 ml of 0.1 mM DPPH solution in a microtube to a final concentration of 1 ppm, stirred, and incubated at 25°C for 30 minutes. ② Afterward, the absorbance St at 517 nm is measured. ③ The sample solution blank is operated in the same manner as when measuring the absorbance St, except that methanol is used instead of the 0.1 mM DPPH solution, and the absorbance So is measured. ④ The blank test is operated in the same manner as when measuring the absorbance St, except that distilled water is used instead of the sample solution, and the absorbance Bt is measured. ⑤ The blank of the blank test is operated in the same manner as when measuring the absorbance St, except that methanol is used instead of the 0.1 mM DPPH solution and distilled water is used instead of the sample solution, and the absorbance Bo is measured.

[0061] The result of the free radical scavenging rate (%) was calculated by the following mathematical formula 1, and the result is as shown in Table 1 below.

[0062] [Mathematical Formula 1]

[0063]

[0064] ■ St: Absorbance at 517 nm after free radical scavenging of the sample solution

[0065] ■ Bt: Absorbance at 517 nm of the blank solution after free radical scavenging

[0066] ■ So : Absorbance at 517 nm before reaction when free radicals are not added to the sample solution

[0067] ■ Bo: Absorbance at 517 nm before reaction of the blank solution without free radical addition

[0069] Experiments were performed using samples prepared according to the composition of the following table. (Unit: ppm)

[0071] <Experimental Example 1> DPPH Radical Scavenging Activity Analysis 1

[0072] Samples were prepared to contain the same total antioxidant content (1 ppm), and the antioxidant effects were compared and evaluated. The specific experimental method is as described in detail in the DPPH radical scavenging activity analysis above.

[0073] Experiments were performed using samples prepared according to the composition of the following table. (Unit: ppm)

[0074] division control group Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7 Example 1 Glutathione - 1 - - - - - - - Vit C - - 1 - - - - - - GAP(Glutamine, Glycine, Cystine) 1) - - - 1 - - - - 0.187 Honokiol - - - - 1 - - - 0.813 Niacinamide - - - - - 1 - 0.714 - Adenosine - - - - - - 1 0.286 - Total (ppm) 0 1 1 1 1 1 1 1 1

[0075] 1) GAP contains Glutamine, Glycine, and Cystine in a weight ratio of 1:1:0.3, respectively.

[0077] The DPPH radical scavenging activity results for the above samples are shown in Table 2 below.

[0078] division OD measurement (average of 3 measurements) Result (%) compared to control group ROS Removal Ability (100 - Result) control group 0.458 100.00 0.00 Comparative Example 1 0.438 95.69 4.31 Comparative Example 2 0.354 77.42 22.58 Comparative Example 3 0.473 103.25 -3.25 Comparative Example 4 0.356 77.80 22.20 Comparative Example 5 0.449 99.98 2.02 Comparative Example 6 0.448 97.86 2.14 Comparative Example 7 0.445 97.19 2.81 Example 1 0.310 67.80 *** 32.20 ***

[0079] ***) Significance compared to Honokiol and Vitamin C alone p < 0.001 (t-test)

[0080] As a result of the experiment, when the antioxidant was treated at a total concentration of 1 ppm, no antioxidant efficacy was observed in Comparative Example 1, treated with glutathione (1 ppm), and Comparative Example 3, treated with GAP (1 ppm). Meanwhile, when honokiol was treated at 1 ppm (Comparative Example 4), it showed an antioxidant effect equivalent to that of Vitamin C (Comparative Example 2). Furthermore, not only was no significant antioxidant activity observed when niacinamide was treated (Comparative Example 5) and when adenosine was treated (Comparative Example 6), but no significant antioxidant activity was also observed when a combination of these was treated at a total concentration of 1 ppm (Comparative Example 7).

[0081] Meanwhile, in the case of Example 1, which combined honokiol (0.813 ppm) and GAP (0.187 ppm) (total 1 ppm), a significantly increased antioxidant effect was observed compared to the case treated with Vitamin C at 1 ppm (Comparative Example 2) (significance p<0.001). Considering that there was no antioxidant effect when only GAP was treated at the same concentration of 1 ppm (Comparative Example 3), and that the case treated with honokiol at 1 ppm (Comparative Example 4) showed only an antioxidant effect equivalent to that of Vitamin C at 1 ppm (Comparative Example 11), this result demonstrates an excellent synergistic effect despite the total concentration of antioxidants being the same.

[0083] <Experimental Example 2> DPPH Radical Scavenging Activity Analysis 2

[0084] Samples were prepared to contain the same total antioxidant content (1 ppm), and the antioxidant effect was compared and evaluated. The evaluation method was the same as in Experimental Example 1 above.

[0085] Experiments were performed using samples prepared according to the composition of the following table. (Unit: ppm)

[0086] division control group Comparative Example 8 Example 2 Glutathoine - - - GAP(Glutamine, Glycine, Cystine) 1) - 0.187 0.187 Honokiol - - 0.813 Niacinamide - 0.813 - Total (ppm) 0 1 1

[0087] 1) GAP contains Glutamine, Glycine, and Cystine in a weight ratio of 1:1:0.3, respectively.

[0088] The DPPH radical scavenging activity results for the above samples are shown in Table 4 below.

[0089] division OD measurement (average of 3 measurements) Result (%) compared to control group ROS Gegeoning (100 - result) control group 0.355 100.0000 0.00 Comparative Example 8 0.370 104.32 -4.32 Example 2 0.304 85.81 ***, # 14.19 ***, #

[0090] ***) Significance compared to the control group p < 0.001 (t-test)

[0091] #) Significance compared to Comparative Example 8 p < 0.001 (t-test)

[0093] As a result of the experiment, it was confirmed that when an antioxidant was treated at a total concentration of 1 ppm, the result of Example 2, which was treated with a combination of GAP and honokiol (1 ppm), was significantly superior to the antioxidant effect of Comparative Example 8, which was treated with a combination of GAP and niacinamide (1 ppm). Furthermore, it was confirmed that the antioxidant effect of the present invention was not only significant compared to the control group (p < 0.001), but also significantly higher compared to Comparative Example 8 (p < 0.001).

[0095] <Experimental Example 3> DPPH Radical Scavenging Activity Analysis 3

[0096] Samples were prepared to contain the same total antioxidant content (1 ppm), and the antioxidant effect was compared and evaluated. The evaluation method was the same as in Experimental Example 1 above.

[0097] Experiments were performed using samples prepared according to the composition of the following table. (Unit: ppm)

[0098] division control group Comparative Example 9 Example 3 Glutathoine - 0.187 - GAP(Glutamine, Glycine, Cystine) 1) - - 0.187 Honokiol - 0.813 0.813 Total (ppm) 0 1 1

[0099] 1) GAP contains Glutamine, Glycine, and Cystine in a weight ratio of 1:1:0.3, respectively.

[0100] The DPPH radical scavenging activity results for the above samples are shown in Table 6 below.

[0101] division OD measurement (average of 3 measurements) Result (%) compared to control group ROS Gegeoning (100 - result) control group 0.241 100 0 Comparative Example 9 0.26 93.51 6.49 Example 3 0.212 87.98 ***, # 12.01 ***, #

[0102] ***) Significance compared to the control group p < 0.001 (t-test)

[0103] #) Significance compared to Comparative Example 9 p < 0.001 (t-test)

[0105] As a result of the experiment, it was confirmed that when the antioxidant was treated at a total concentration of 1 ppm, the result of Example 3, which was treated with a combination of GAP and honokiol (1 ppm), was significantly superior to the antioxidant effect of Comparative Example 9, which was treated with a combination of glutathione and honokiol (1 ppm). Furthermore, it was confirmed that the antioxidant effect of the present invention was not only significant compared to the control group (p < 0.001), but also significantly higher compared to Comparative Example 9 (p < 0.001).

[0106] These results reflect that the synergistic oxidative effect by the combination of honokiol and GAP is not provided merely through its function as a precursor of glutathione, but is an unexpected and significant synergistic effect by the combination of honokiol and GAP of the present invention.

[0108] Although embodiments of the present invention have been described above with reference to the attached drawings, those skilled in the art will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

Claim 1 A cosmetic composition comprising a glutathione precursor and a magnolia-derived lignan compound, wherein the glutathione precursor comprises cysteine ​​or cystine, glutamine, and glycine, the magnolia-derived lignan compound is honokiol, and the glutathione precursor and the magnolia-derived lignan compound are included in a weight ratio of 1:0.1 to 30. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 A cosmetic composition according to claim 1, characterized in that the glutathione precursor is included in an amount of 0.000001 to 10 weight% based on the total weight of the cosmetic composition, and the magnolia-derived lignan compound is included in an amount of 0.000001 to 10 weight% based on the total weight of the cosmetic composition. Claim 6 delete Claim 7 A cosmetic composition according to claim 1, characterized in that the cosmetic composition is for one or more uses selected from the group consisting of skin wrinkle improvement, skin elasticity improvement, skin moisture improvement, skin barrier improvement, inflammation inhibition, and antioxidant. Claim 8 A cosmetic composition according to claim 1, characterized in that the cosmetic composition is one or more formulations selected from the group consisting of softening lotion, nourishing lotion, astringent lotion, skin toner, lotion, essence, cream, massage cream, pack, makeup base, BB cream, foundation, powder, cleansing foam, cleansing cream, and cleansing water.

Images